Inês Araújo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Inês Araújo has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Cândida Fonseca
Heart Failure Clínic, S. Francisco Xavier Hospital, Department of Medicine, ULS Lisboa Ocidental, NOVA Medical School, Universidade Nova de Lisboa, 1150-190 Lisboa, Portugal
3 shared publications - Carmen Jiménez López-Guarch
Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
2 shared publications - Celia Coelho Henriques
Department of Internal Medicine 2, Curry Cabral Hospital, Lisbon, Portugal
2 shared publications Cândida Fonseca
Heart Failure Unit, Internal Medicine Department, São Francisco Xavier Hospital - Western Lisbon Hospital Centre (CHLO), Estrada do Forte do Alto do Duque, 1449-005, Lisbon, Portugal
2 shared publications- Inês Egídio de Sousa
Internal Medicine Department, Hospital São Francisco Xavier, Lisbon, PRT
2 shared publications - Marta Roldão
Internal Medicine Department, Hospital São Francisco Xavier, Lisbon, PRT
2 shared publications
Latest Publications
- Open Access
- 10 February 2023
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 36 (3) , 193-201
Co-Administration of Albumin and Furosemide in Acute Heart Failure with Diuretic Resistance
Acute heart failure is a frequent cause of hospital admission in Portugal, and has an increasing tendency given the aging population. Although most admissions for acute heart failure are caused by congestive conditions, not all patients have a congestive phenotype, reflecting the complexity of a process with multiple pathophysiological pathways. The use of diuretics, usually loop diuretics, is the mainstay of treatment for congestion. However, many patients develop resistance, thus constituting a challenge with no consensual solution to date, despite extensive debate over the years. Despite its frequent use in clinical practice, the co-administration of albumin and furosemide remains controversial in the management of patients with acute heart failure, hypoalbuminemia, and diuretic resistance. This review addresses the pathophysiological mechanisms of congestion in patients with acute heart failure and explores the theoretical basis that supports the co-administration of albumin and furosemide in this clinical context. It is intended to clarify the potential benefit of the combined approach in this specific population and identify possible gaps in the literature that could be the subject of future studies.
- 10 February 2023
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 36 (3) , 193-201
Open AccessCo-Administration of Albumin and Furosemide in Acute Heart Failure with Diuretic Resistance
Acute heart failure is a frequent cause of hospital admission in Portugal, and has an increasing tendency given the aging population. Although most admissions for acute heart failure are caused by congestive conditions, not all patients have a congestive phenotype, reflecting the complexity of a process with multiple pathophysiological pathways. The use of diuretics, usually loop diuretics, is the mainstay of treatment for congestion. However, many patients develop resistance, thus constituting a challenge with no consensual solution to date, despite extensive debate over the years. Despite its frequent use in clinical practice, the co-administration of albumin and furosemide remains controversial in the management of patients with acute heart failure, hypoalbuminemia, and diuretic resistance. This review addresses the pathophysiological mechanisms of congestion in patients with acute heart failure and explores the theoretical basis that supports the co-administration of albumin and furosemide in this clinical context. It is intended to clarify the potential benefit of the combined approach in this specific population and identify possible gaps in the literature that could be the subject of future studies.
- Open Access
- 30 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21734
Predicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis
The marked increase in life expectancy seen in Portugal in the last five decades led to a change in the profile of patients being most commonly admitted in internal medicine wards. In deciding the best care for these patients, prognostication models are needed in order to reduce readmissions, mortality, and adequate care. We aimed to study short and long-term mortality and predictors of all-cause mortality, independently of cause admission, of patients admitted in an internal medicine ward. This two-part, single-center study enrolled patients from October 2013 to October 2014 with a follow-up of 60 months. A total of 681 patients were included; the mean age was 75.86 years with 60.4% females. The most frequent comorbidities were anemia, hypertension, and renal impairment. More than half of the population died in the follow-up period (51.5%). Deaths were significantly higher in the first six months after discharge (53% of all deaths) and then decreased abruptly to 11.6% in the second half-year after discharge. Based on the multivariate logistic regression model, with age over 80 years, anemia and neoplasm were independent predictors of short-term (p<0.001, p=0.001, p<0.001, respectively) and long-term (p<0.001 for the three conditions) mortality. Heart failure (p=0.018) and diabetes (p=0.025) were also predictors of long-term mortality. High mortality, mainly in the first six months after discharge, elicits strategies targeting transition of care and close follow-up in the first months, which can be the key to improving outcomes. Identification of patients at higher risk may help design realistic models aiming to improve care for this frail population and decrease morbimortality.
- 30 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21734
Open AccessPredicting Prognosis in Internal Medicine: A Short and Long-Term Mortality Comparison Analysis
The marked increase in life expectancy seen in Portugal in the last five decades led to a change in the profile of patients being most commonly admitted in internal medicine wards. In deciding the best care for these patients, prognostication models are needed in order to reduce readmissions, mortality, and adequate care. We aimed to study short and long-term mortality and predictors of all-cause mortality, independently of cause admission, of patients admitted in an internal medicine ward. This two-part, single-center study enrolled patients from October 2013 to October 2014 with a follow-up of 60 months. A total of 681 patients were included; the mean age was 75.86 years with 60.4% females. The most frequent comorbidities were anemia, hypertension, and renal impairment. More than half of the population died in the follow-up period (51.5%). Deaths were significantly higher in the first six months after discharge (53% of all deaths) and then decreased abruptly to 11.6% in the second half-year after discharge. Based on the multivariate logistic regression model, with age over 80 years, anemia and neoplasm were independent predictors of short-term (p<0.001, p=0.001, p<0.001, respectively) and long-term (p<0.001 for the three conditions) mortality. Heart failure (p=0.018) and diabetes (p=0.025) were also predictors of long-term mortality. High mortality, mainly in the first six months after discharge, elicits strategies targeting transition of care and close follow-up in the first months, which can be the key to improving outcomes. Identification of patients at higher risk may help design realistic models aiming to improve care for this frail population and decrease morbimortality.
- Open Access
- 26 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Palliative Care in Heart Failure: Challenging Prognostication
Heart failure (HF) is a chronic progressive disease with high morbimortality and poor quality of life (QoL). Palliative care significantly improves clinical outcomes but few patients receive it, in part due to challenging decisions about prognosis. This retrospective study, included all patients consecutively discharged from an Acute Heart Failure Unit over a period of one year, aiming to assess the accuracy of the Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC) score in predicting mortality. Additionally, predictors of death at one and three years were explored using a multivariate regression model. The MAGGIC score was useful in predicting mortality, without significant difference between mortality observed at three-years follow-up compared with a mortality given by the score (p=0.115). Selected variables were statistically compared showing that poor functional status, high New York Heart Association (NYHA) at discharge, psychopharmacs use, and high creatininemia were associated with higher mortality (p<0.05). The multivariate regression model identified three predictors of one-year mortality: psychopharmacs baseline use (OR=4.110; p=0.014), angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) medication at discharge (OR=0.297; p=0.033), and higher admission's creatinine (OR=2.473; p=0.028). For three-year mortality outcome, two variables were strong independent predictors: psychopharmacs (OR=3.330; p=0.022) and medication with ACEI/ARB at discharge (OR=0.285; p=0.018). Models’ adjustment was assessed through the receiver operating characteristic (ROC) curve. The best model was the one-year mortality (area under the curve, AUC 81%), corresponding to a good discrimination power. Despite prognostication, when setting goals of care an individualised patient-centred approach is imperative, based on the patient’s objectives and needs. Risk factors related to poorer outcomes should be considered, in particular, higher NYHA at discharge which also represents symptom burden. Hospitalisation is an opportunity to optimize global care for heart failure patients including palliative care.
- 26 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Open AccessPalliative Care in Heart Failure: Challenging Prognostication
Heart failure (HF) is a chronic progressive disease with high morbimortality and poor quality of life (QoL). Palliative care significantly improves clinical outcomes but few patients receive it, in part due to challenging decisions about prognosis. This retrospective study, included all patients consecutively discharged from an Acute Heart Failure Unit over a period of one year, aiming to assess the accuracy of the Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC) score in predicting mortality. Additionally, predictors of death at one and three years were explored using a multivariate regression model. The MAGGIC score was useful in predicting mortality, without significant difference between mortality observed at three-years follow-up compared with a mortality given by the score (p=0.115). Selected variables were statistically compared showing that poor functional status, high New York Heart Association (NYHA) at discharge, psychopharmacs use, and high creatininemia were associated with higher mortality (p<0.05). The multivariate regression model identified three predictors of one-year mortality: psychopharmacs baseline use (OR=4.110; p=0.014), angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) medication at discharge (OR=0.297; p=0.033), and higher admission's creatinine (OR=2.473; p=0.028). For three-year mortality outcome, two variables were strong independent predictors: psychopharmacs (OR=3.330; p=0.022) and medication with ACEI/ARB at discharge (OR=0.285; p=0.018). Models’ adjustment was assessed through the receiver operating characteristic (ROC) curve. The best model was the one-year mortality (area under the curve, AUC 81%), corresponding to a good discrimination power. Despite prognostication, when setting goals of care an individualised patient-centred approach is imperative, based on the patient’s objectives and needs. Risk factors related to poorer outcomes should be considered, in particular, higher NYHA at discharge which also represents symptom burden. Hospitalisation is an opportunity to optimize global care for heart failure patients including palliative care.
- Open Access
- 20 September 2021
- Published by Sociedade Portuguesa de Medicina Interna in Medicina Interna
- Vol. 28 (1) , 76-81
Checklist para A Pré-Alta de Internamento por Insuficiência Cardíaca
A insuficiência cardíaca (IC) é um problema grave de saúde pública em Portugal, estando associada a elevada morbilidade e mortalidade. A gestão clínica do doente com IC é complexa, sendo necessário melhorar a consciencialização para a doença e a articulação entre os cuidados de saúde. Os doentes com IC são frequentemente hospitalizados devido a episódios agudos da doença. Estes internamentos são uma oportunidade para a otimização da abordagem da IC. De acordo com as recomendações internacionais, devem ser utilizadas checklists na gestão dos doentes com IC em contexto hospitalar, para melhorar a gestão clínica do doente e diminuir o impacto clínico e financeiro desta síndrome. Neste position statement o Núcleo de Estudos de Insuficiência Cardíaca (NEIC) da Sociedade Portuguesa de Medicina Interna (SPMI) propõe uma checklist para a pré-alta hospitalar para melhorar a abordagem do doente internado por IC em Portugal. A checklist proposta teve em conta as recomendações internacionais para a abordagem da IC, adaptando-as à realidade da prática clínica, epidemiologia e demografia de Portugal.
- 20 September 2021
- Published by Sociedade Portuguesa de Medicina Interna in Medicina Interna
- Vol. 28 (1) , 76-81
Open AccessChecklist para A Pré-Alta de Internamento por Insuficiência Cardíaca
A insuficiência cardíaca (IC) é um problema grave de saúde pública em Portugal, estando associada a elevada morbilidade e mortalidade. A gestão clínica do doente com IC é complexa, sendo necessário melhorar a consciencialização para a doença e a articulação entre os cuidados de saúde. Os doentes com IC são frequentemente hospitalizados devido a episódios agudos da doença. Estes internamentos são uma oportunidade para a otimização da abordagem da IC. De acordo com as recomendações internacionais, devem ser utilizadas checklists na gestão dos doentes com IC em contexto hospitalar, para melhorar a gestão clínica do doente e diminuir o impacto clínico e financeiro desta síndrome. Neste position statement o Núcleo de Estudos de Insuficiência Cardíaca (NEIC) da Sociedade Portuguesa de Medicina Interna (SPMI) propõe uma checklist para a pré-alta hospitalar para melhorar a abordagem do doente internado por IC em Portugal. A checklist proposta teve em conta as recomendações internacionais para a abordagem da IC, adaptando-as à realidade da prática clínica, epidemiologia e demografia de Portugal.
- 14 March 2019
- Published by Springer Nature in Sleep and Breathing
- Vol. 23 (4) , 1307-1308
Usefulness of home sleep apnea tests in heart failure patients
- 14 March 2019
- Published by Springer Nature in Sleep and Breathing
- Vol. 23 (4) , 1307-1308
Usefulness of home sleep apnea tests in heart failure patients
- 17 January 2018
- Published by Springer Nature in Sleep and Breathing
- Vol. 22 (3) , 749-755
Diagnosis of sleep apnea in patients with stable chronic heart failure using a portable sleep test diagnostic device
Purpose ApneaLink is a portable device for the screening of sleep apnea, a prevalent and underdiagnosed comorbidity in heart failure patients. A prospective cross-sectional study in patients with chronic heart failure was carried out to assess the sensitivity and specificity of apnea-hypopnea index (AHI) measurements using ApneaLink against the standard polysomnography test. Methods Adult patients with a prior hospitalization in an acute heart failure hospital unit were recruited for the study. All participants were tested for sleep apnea using ApneaLink and polysomnography simultaneously during an overnight stay at a sleep laboratory. Global sleep apnea was evaluated according to the AHI, which was analyzed and compared. Subpopulation comparison based on ejection fraction was not realized due to population size. Results Thirty-five patients with stable chronic heart failure completed the study (mean age 70.9 ± 10.5 years and body mass index 30.0 ± 4.7 kg/m2). Two patients were excluded due to insufficient study duration. ApneaLink had a sensitivity greater than 80% for all AHI measurements, and a specificity greater than 80% for all AHI measurements, except for AHI ≥ 5 events/h (61.5%). The results showed higher sensitivities and specificities at AHI values of ≥ 10 events/h (sensitivity 81.3% and specificity 84.2%) and ≥ 15 events/h (sensitivity 83.3% and specificity 91.3%). Correlation analysis showed that AHI measurements using ApneaLink and polysomnography had a strong and significant correlation (r = 0.794; P < 0.001). Conclusions Our results suggest that ApneaLink could be used in clinical practice to identify heart failure patients with high (AHI ≥ 15 events/h) and low (AHI < 5 events/h) probability of having sleep apnea, sparing the need for a diagnostic polysomnography and thus potentially impacting prognosis by providing a more cost-effective and timely diagnosis of this non-cardiac comorbidity.
- 17 January 2018
- Published by Springer Nature in Sleep and Breathing
- Vol. 22 (3) , 749-755
Diagnosis of sleep apnea in patients with stable chronic heart failure using a portable sleep test diagnostic device
Purpose ApneaLink is a portable device for the screening of sleep apnea, a prevalent and underdiagnosed comorbidity in heart failure patients. A prospective cross-sectional study in patients with chronic heart failure was carried out to assess the sensitivity and specificity of apnea-hypopnea index (AHI) measurements using ApneaLink against the standard polysomnography test. Methods Adult patients with a prior hospitalization in an acute heart failure hospital unit were recruited for the study. All participants were tested for sleep apnea using ApneaLink and polysomnography simultaneously during an overnight stay at a sleep laboratory. Global sleep apnea was evaluated according to the AHI, which was analyzed and compared. Subpopulation comparison based on ejection fraction was not realized due to population size. Results Thirty-five patients with stable chronic heart failure completed the study (mean age 70.9 ± 10.5 years and body mass index 30.0 ± 4.7 kg/m2). Two patients were excluded due to insufficient study duration. ApneaLink had a sensitivity greater than 80% for all AHI measurements, and a specificity greater than 80% for all AHI measurements, except for AHI ≥ 5 events/h (61.5%). The results showed higher sensitivities and specificities at AHI values of ≥ 10 events/h (sensitivity 81.3% and specificity 84.2%) and ≥ 15 events/h (sensitivity 83.3% and specificity 91.3%). Correlation analysis showed that AHI measurements using ApneaLink and polysomnography had a strong and significant correlation (r = 0.794; P < 0.001). Conclusions Our results suggest that ApneaLink could be used in clinical practice to identify heart failure patients with high (AHI ≥ 15 events/h) and low (AHI < 5 events/h) probability of having sleep apnea, sparing the need for a diagnostic polysomnography and thus potentially impacting prognosis by providing a more cost-effective and timely diagnosis of this non-cardiac comorbidity.
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 6 (6) , 495-501
Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series
To present 18 new cases of human immunodeficiency virus (HIV)-related pulmonary arterial hypertension (PAH) with presenting features, treatment options and follow-up data. This is a single-centre, retrospective, observational study that used prospectively collected data, conducted during a 14-year period on HIV-related PAH patients who were referred to a pulmonary hypertension unit. All patients infected with HIV were consecutively admitted for an initial evaluation of PAH during the study period and included in our study. Right heart catheterisation was used for the diagnosis of PAH. Specific PAH treatment was started according to the physician's judgment and the recommendations for idiopathic PAH. The data collected included demographic characteristics, parameters related to both HIV infection and PAH and disease follow-up. Eighteen patients were included. Intravenous drug use was the major risk factor for HIV infection. Risk factors for PAH, other than HIV infection, were present in 55.5% patients. The elapsed time between HIV infection and PAH diagnoses was 12.2 ± 6.9 years. At PAH diagnosis, 94.1% patients had a CD4 cell count > 200 cells/μL. Highly active antiretroviral therapy (present in 47.1% patients) was associated with an accelerated onset of PAH. Survival rates were 93.8%, 92.9% and 85.7% at one, two and three years, respectively. Concerning specific therapy, 33.3% of the patients were started on a prostacyclin analogue, and the rest were on oral drugs, mainly phosphodiesterase-5 inhibitors. During the follow-up period, specific therapy was de-escalated to oral drugs in all of the living patients. The survival rates of HIV-related PAH patients were higher, most likely due to new aggressive specific therapy. The majority of patients were on oral specific therapy and clinically stable. Moreover, sildenafil appears to be a safe therapy for less severe HIV-related PAH.
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 6 (6) , 495-501
Open AccessPulmonary arterial hypertension related to human immunodeficiency virus infection: A case series
To present 18 new cases of human immunodeficiency virus (HIV)-related pulmonary arterial hypertension (PAH) with presenting features, treatment options and follow-up data. This is a single-centre, retrospective, observational study that used prospectively collected data, conducted during a 14-year period on HIV-related PAH patients who were referred to a pulmonary hypertension unit. All patients infected with HIV were consecutively admitted for an initial evaluation of PAH during the study period and included in our study. Right heart catheterisation was used for the diagnosis of PAH. Specific PAH treatment was started according to the physician's judgment and the recommendations for idiopathic PAH. The data collected included demographic characteristics, parameters related to both HIV infection and PAH and disease follow-up. Eighteen patients were included. Intravenous drug use was the major risk factor for HIV infection. Risk factors for PAH, other than HIV infection, were present in 55.5% patients. The elapsed time between HIV infection and PAH diagnoses was 12.2 ± 6.9 years. At PAH diagnosis, 94.1% patients had a CD4 cell count > 200 cells/μL. Highly active antiretroviral therapy (present in 47.1% patients) was associated with an accelerated onset of PAH. Survival rates were 93.8%, 92.9% and 85.7% at one, two and three years, respectively. Concerning specific therapy, 33.3% of the patients were started on a prostacyclin analogue, and the rest were on oral drugs, mainly phosphodiesterase-5 inhibitors. During the follow-up period, specific therapy was de-escalated to oral drugs in all of the living patients. The survival rates of HIV-related PAH patients were higher, most likely due to new aggressive specific therapy. The majority of patients were on oral specific therapy and clinically stable. Moreover, sildenafil appears to be a safe therapy for less severe HIV-related PAH.
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 6 (6) , 503
Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 6 (6) , 503
Open AccessPulmonary arterial hypertension related to human immunodeficiency virus infection: A case series
- 6 January 2012
- Published by Taylor & Francis in Biomarkers
- Vol. 17 (2) , 180-185
Assessment of risk factors for in-hospital mortality after intensive care unit discharge
Context: Post-intensive care unit (ICU) mortality predictors are unknown. Objective: To assess post-ICU in-hospital mortality predictors. Materials and methods: Analysis of 296 patients discharged alive from a medical-surgical ICU during an 18-month period. Results: Post-ICU in-hospital mortality was 22.6%. Nonsurvivors had significantly higher Charlson comorbidity score and more often had a tracheostomy. C-reactive protein (CRP) “alert measurement”, ≥ 6 mg/dL, independently discriminated survivors from nonsurvivors. Discussion: A CRP “alert measurement” or the need for tracheostomy may be used to identify patients with high risk of dying after ICU discharge. Conclusions: Charlson comorbidity score, CRP and tracheostomy predicted post-ICU in-hospital mortality.
- 6 January 2012
- Published by Taylor & Francis in Biomarkers
- Vol. 17 (2) , 180-185
Assessment of risk factors for in-hospital mortality after intensive care unit discharge
Context: Post-intensive care unit (ICU) mortality predictors are unknown. Objective: To assess post-ICU in-hospital mortality predictors. Materials and methods: Analysis of 296 patients discharged alive from a medical-surgical ICU during an 18-month period. Results: Post-ICU in-hospital mortality was 22.6%. Nonsurvivors had significantly higher Charlson comorbidity score and more often had a tracheostomy. C-reactive protein (CRP) “alert measurement”, ≥ 6 mg/dL, independently discriminated survivors from nonsurvivors. Discussion: A CRP “alert measurement” or the need for tracheostomy may be used to identify patients with high risk of dying after ICU discharge. Conclusions: Charlson comorbidity score, CRP and tracheostomy predicted post-ICU in-hospital mortality.
- Open Access
- 21 October 2011
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 11 (1) , 64
Giant pulmonary artery aneurysm in a patient with vasoreactive pulmonary hypertension: a case report
Pulmonary artery aneurysms are a rare condition, frequently associated with pulmonary hypertension. However, the evolution and treatment of this pathology is still not clear.
- 21 October 2011
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 11 (1) , 64
Open AccessGiant pulmonary artery aneurysm in a patient with vasoreactive pulmonary hypertension: a case report
Pulmonary artery aneurysms are a rare condition, frequently associated with pulmonary hypertension. However, the evolution and treatment of this pathology is still not clear.